semaglutide side effect class action in kentucky glp-1 gastrointestinal obstruction law office glp-1 law firm in kentucky glp-1 gastrointestinal obstruction law office in kentucky as a GLP-1 Agonist: A Breakthrough-150cent Weight Loss Drugs Lawsuit |

Differences among the drugs became more noticeable in the comparative pattern: Semaglutide showed a 42% lower risk of worsening mental illness Liraglutide showed about an 18% lower risk Exenatide and dulaglutide did not show similarly strong reductions in the summarized reports Such variation suggests outcomes may not be consistent across every drug in the GLP-1 category

doi: 10.1038/srep18761

GLP-1 receptor agonists are expected to remain the main class of anti-obesity drugs and dominate the space for at least the next several years, and several startups with GLP-1 assets have debuted over the past few years

"Expanding our virtual healthcare platform to include weight management is part of our ongoing commitment to listening to patients and the services they want from their local pharmacy," said Rick Gates, chief pharmacy officer at Walgreens